نتائج البحث - Joseph Muenzer

تنقيح النتائج
  1. 1
    Overview of the mucopolysaccharidoses

    Overview of the mucopolysaccharidoses حسب Joseph Muenzer

    منشور في 2011
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Early initiation of enzyme replacement therapy for the mucopolysaccharidoses

    Early initiation of enzyme replacement therapy for the mucopolysaccharidoses حسب Joseph Muenzer

    منشور في 2013
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Plain language summary of a study looking at whether genetic testing can help doctors diagnose the severity of mucopolysaccharidosis type I (MPS I)

    Plain language summary of a study looking at whether genetic testing can help doctors diagnose the severity of mucopolysaccharidosis type I (MPS I) حسب Lorne A. Clarke, Roberto Giugliani, Joseph Muenzer

    منشور في 2023
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Plain language summary of a study looking at the age at diagnosis and time to start of treatment in individuals with mucopolysaccharidosis type I (MPS I)

    Plain language summary of a study looking at the age at diagnosis and time to start of treatment in individuals with mucopolysaccharidosis type I (MPS I) حسب Roberto Giugliani, Nicole Muschol, Mark Dant, Joseph Muenzer

    منشور في 2022
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Purification of proline-rich proteins from parotid glands of isoproterenol-treated rats.

    Purification of proline-rich proteins from parotid glands of isoproterenol-treated rats. حسب Joseph Muenzer, C Bildstein, Marie M. Gleason, Don M. Carlson

    منشور في 1979
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Properties of proline-rich proteins from parotid glands of isoproterenol-treated rats.

    Properties of proline-rich proteins from parotid glands of isoproterenol-treated rats. حسب Joseph Muenzer, C Bildstein, Marie M. Gleason, Don M. Carlson

    منشور في 1979
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I

    Improvement in time to treatment, but not time to diagnosis, in patients with mucopolysaccharidosis type I حسب Roberto Giugliani, Nicole Muschol, Hillary A. Keenan, Mark Dant, Joseph Muenzer

    منشور في 2020
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome

    The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome حسب Julie B. Eisengart, Kelly King, Elsa Shapiro, C B Whitley, Joseph Muenzer

    منشور في 2019
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice

    Mannitol-facilitated CNS entry of rAAV2 vector significantly delayed the neurological disease progression in MPS IIIB mice حسب Douglas M. McCarty, Julianne DiRosario, Kadra Gulaid, Joseph Muenzer, Haiyan Fu

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)

    Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS) حسب Joseph Muenzer, Roberto Giugliani, Maurizio Scarpa, Anna Tylki‐Szymańska, Virginie Jego, Michael Beck

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)

    Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome... حسب Joseph Muenzer, Jaco Botha, Paul Harmatz, Roberto Giugliani, Christoph Kampmann, Barbara K. Burton

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    Impact of the COVID-19 pandemic on the standard of care for patients with lysosomal storage diseases: A survey of healthcare professionals in the Fabry, Gaucher, and Hunter Outcome Survey registries

    Impact of the COVID-19 pandemic on the standard of care for patients with lysosomal storage diseases: A survey of healthcare professionals in the Fabry, Gaucher, and Hunter Outcome... حسب Deborah Elstein, Roberto Giugliani, Joseph Muenzer, Jörn Schenk, Ida Vanessa Döederlein Schwartz, Christina Anagnostopoulou

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Initial report from the Hunter Outcome Survey

    Initial report from the Hunter Outcome Survey حسب J. E. Wraith, Michael Beck, Roberto Giugliani, Joe T.R. Clarke, Rick Martin, Joseph Muenzer

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    The natural history of MPS I: global perspectives from the MPS I Registry

    The natural history of MPS I: global perspectives from the MPS I Registry حسب Michael Beck, Pamela Arn, Roberto Giugliani, Joseph Muenzer, Torayuki Okuyama, J. Michael Taylor, Shari Fallet

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Neurological Correction of Lysosomal Storage in a Mucopolysaccharidosis IIIB Mouse Model by Adeno-associated Virus-Mediated Gene Delivery

    Neurological Correction of Lysosomal Storage in a Mucopolysaccharidosis IIIB Mouse Model by Adeno-associated Virus-Mediated Gene Delivery حسب Haiyan Fu, R. Jude Samulski, Thomas J. McCown, Yoana J. Picornell, David Fletcher, Joseph Muenzer

    منشور في 2002
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    PO-0096 Clinical Effectiveness Of Idursulfase In Boys Aged 0–5 Years With Hunter Syndrome: 3-year Data From The Hunter Outcome Survey

    PO-0096 Clinical Effectiveness Of Idursulfase In Boys Aged 0–5 Years With Hunter Syndrome: 3-year Data From The Hunter Outcome Survey حسب Joseph Muenzer, Roberto Giugliani, Maurizio Scarpa, Akemi Tanaka, A Anna Tylki-Szymanska, Isabelle Morin, Michael Beck

    منشور في 2014
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain

    Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain حسب Haiyan Fu, Joseph Muenzer, R. Jude Samulski, George R. Breese, Jerillyn Sifford, Xinhua Zeng, Douglas M. McCarty

    منشور في 2003
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey

    Idursulfase treatment of Hunter syndrome in children younger than 6 years: Results from the Hunter Outcome Survey حسب Joseph Muenzer, Michael Beck, Roberto Giugliani, Yasuyuki Suzuki, Anna Tylki‐Szymańska, Vassili Valayannopoulos, Ashok Vellodi, J. E. Wraith

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide

    A charitable access program for patients with lysosomal storage disorders in underserved communities worldwide حسب Atul Mehta, Uma Ramaswami, Joseph Muenzer, Roberto Giugliani, Kurt Ullrich, Tanya Collin-Histed, Zoya Panahloo, Hartmann Wellhoefer, Joel Frader

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Safety and Feasibility of High-pressure Transvenous Limb Perfusion With 0.9% Saline in Human Muscular Dystrophy

    Safety and Feasibility of High-pressure Transvenous Limb Perfusion With 0.9% Saline in Human Muscular Dystrophy حسب Zheng Fan, Keith C. Kocis, Robert D. Valley, James F. Howard, Manisha Chopra, Hongyu An, Weili Lin, Joseph Muenzer, William J. Powers

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: